Rothschild Hospital
- Address
- lock Available on a paid plan
Neoplasms and Ophthalmic Oncology
The Rothschild Hospital in Paris is conducting clinical research in neoplasms focused on retinoblastoma, with an emphasis on conservative care and preserving vision. These studies explore how different treatment approaches can improve local disease control while supporting better visual outcomes for patients.
- Conservative treatment strategies for retinoblastoma
- Evaluation of visual function and patient outcomes
- Testing the effectiveness of new management approaches for local disease control
Research in this area aims to refine treatment choices for children and families by balancing cancer control with eye preservation.
Otorhinolaryngologic Diseases and Hearing Disorders
Clinical trials at this site also address otorhinolaryngologic diseases, particularly sudden sensorineural hearing loss. The work is centered on finding ways to improve early hearing recovery and assess whether simple supportive treatments can enhance short-term hearing outcomes.
- Study of sudden sensorineural hearing loss in ENT emergency patients
- Assessment of hearing threshold improvement after early treatment
- Evaluating treatment effectiveness for rapid-onset sensorineural hearing loss
These investigations focus on improving diagnostic follow-up and treatment response in urgent ear and hearing conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Rothschild Hospital
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Intra-Arterial Chemotherapy with Topotecan and Drug Combination for Conservative Management of Retinoblastoma in Eligible Patients | Institut Curie | Phase II | Recruiting | Mar 2021 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.